| 000 | 01362 a2200373 4500 | ||
|---|---|---|---|
| 005 | 20250513062620.0 | ||
| 264 | 0 | _c19940422 | |
| 008 | 199404s 0 0 eng d | ||
| 022 | _a0066-4804 | ||
| 024 | 7 |
_a10.1128/AAC.38.1.31 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPfefferkorn, E R | |
| 245 | 0 | 0 |
_aComparison of mutants of Toxoplasma gondii selected for resistance to azithromycin, spiramycin, or clindamycin. _h[electronic resource] |
| 260 |
_bAntimicrobial agents and chemotherapy _cJan 1994 |
||
| 300 |
_a31-7 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAzithromycin _xpharmacology |
| 650 | 0 | 4 | _aCells, Cultured |
| 650 | 0 | 4 |
_aClindamycin _xpharmacology |
| 650 | 0 | 4 | _aDrug Resistance, Microbial |
| 650 | 0 | 4 |
_aFibroblasts _xmicrobiology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLeucine _xmetabolism |
| 650 | 0 | 4 | _aMutation |
| 650 | 0 | 4 |
_aOxygen Consumption _xdrug effects |
| 650 | 0 | 4 |
_aRibosomes _xdrug effects |
| 650 | 0 | 4 |
_aSpiramycin _xpharmacology |
| 650 | 0 | 4 |
_aToxoplasma _xdrug effects |
| 650 | 0 | 4 |
_aUracil _xmetabolism |
| 700 | 1 | _aBorotz, S E | |
| 773 | 0 |
_tAntimicrobial agents and chemotherapy _gvol. 38 _gno. 1 _gp. 31-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1128/AAC.38.1.31 _zAvailable from publisher's website |
| 999 |
_c8140897 _d8140897 |
||